Discovery Stems From Here

We are delighted to announce plans to open a new operational hub in the United States. The site will open in the fall of 2018 and will help to support Axol’s customer base in the United States and Canada.

Cambridge, UK – (17th July 2018) – Axol Bioscience, the human cell culture specialists, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.

Neuropathic pain is a debilitating side effect of many commonly-used chemotherapy drugs, and in severe cases can result in the discontinuation of a cancer treatment. By understanding the mechanisms through which chemotherapeutics induce neuropathic pain, researchers aim to develop effective treatments designed specifically to alleviate the condition. These will combat the dose-limitation imposed on chemotherapeutics, as well as offering utility for conditions including multiple sclerosis, diabetes and HIV.

Many commonly used chemotherapy drugs cause unpleasant side effects and complications. Of these, neuropathic pain can be particularly debilitating. Most of the current treatments for neuropathic pain are medications that were originally approved for other health disorders, such as anti-depressants and anti-seizure drugs. These have their own accompanying problems, and since no single drug is effective against all forms of neuropathic pain, it is essential that new therapeutic agents are developed specifically for the treatment of this condition.

Through the previous blogs in this series, we have understood the challenges which somatic cells face when changing their career path to become induced pluripotent stem cells (iPSCs), the ways in which we can induce this change, and how we might assess whether this is the right career for the cells through pluripotency and differentiation assays.